Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences amends Hercules loan, extends maturity to September 2030

Neutral Impact 3 of 5 financing Written later

Arcus Biosciences entered into a First Amendment to its August 27, 2024 Loan and Security Agreement with Hercules Capital and the lenders, which governs the remaining $150.0 million of term loan commitments. The amendment ties the timing of future borrowing to set dates and to clinical and regulatory milestones, extends the maturity date to September 1, 2030, and adds performance covenants that apply if term loan advances exceed $200.0 million.

Key points

  • Maturity date extended to September 1, 2030, with no further extension right.
  • Remaining $150.0 million of term loan commitments: $25.0 million available through March 15, 2026, $25.0 million through September 15, 2026, and up to $50.0 million each after a Phase 3 Clinical Milestone and after FDA approval (Milestone I
  • Covenants apply if advances exceed $200.0 million, starting with quarterly statements three quarters after Milestone I: market capitalization of at least $1.5 billion plus Qualified Cash of at least 50.0% of secured obligations, or Qualifie

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECDec 18, 2025, 4:05 PM ET
Accession number0001724521-25-000122

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 18, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.